Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, Simon J. Harrison et al.|Clinical Cancer Research|2019Cited by 71